HC Wainwright Predicts Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Aktis Oncology in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst R. Burns expects that the technology company will post earnings per share of ($0.54) for the quarter. HC Wainwright currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.63) EPS.

Other equities research analysts have also issued reports about the company. TD Cowen started coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Bank of America assumed coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 price target on the stock. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Leerink Partners began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Aktis Oncology has a consensus rating of “Buy” and a consensus price target of $32.00.

Aktis Oncology Trading Up 8.2%

Shares of NASDAQ AKTS opened at $17.89 on Wednesday. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $29.16. The stock’s 50 day moving average is $19.19.

Insider Activity

In other Aktis Oncology news, Director Helen Susan Kim bought 835,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the purchase, the director owned 5,671,825 shares in the company, valued at $102,092,850. This represents a 17.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This trade represents a 12.17% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 6,117,776 shares of company stock valued at $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.